Walmart notes changes in food purchases among users of the popular weight loss drug Ozempic, predicting broader market impacts. Photo by Marques Thomas.
Walmart U.S. CEO John Furner commented on a perceived shift in food buying patterns among consumers using weight loss drugs like Ozempic, observing a slight reduction in the overall food basket and calorie intake. As these appetite-curbing drugs gain traction, projections suggest that 7% of the U.S. population might use them by 2035. However, a counterpoint by @DisruptorStocks suggests that these GLP-1 drugs are being wrongfully blamed. They highlight that year-over-year volume changes in various food categories are down across the board, not solely due to appetite suppression in a segment of the population.
A problem in search of a solution that creates a unique new problem. My far out prediction: Ozempic causes a decline in grocery freight volumes. pic.twitter.com/CX2aiviLpd
GLP-1s like Ozempic and Wegovy are being used as a scapegoat for many industries.
Don’t believe this Narrative.
Here are YoY volume changes of various food categories. As you can see they are nearly down Across the Board. This is not due to appetite suppression for a small… https://t.co/WERv9oNmmdpic.twitter.com/9iekpeX01q
The US labor market is showing signs of stabilization as the rate of voluntary job quitting approaches pre-pandemic levels and employers implement better retention strategies.
